1.
Br J Haematol
; 204(3): 939-944, 2024 Mar.
Article
in English
| MEDLINE
| ID: mdl-38054248
ABSTRACT
Trisomy karyotype occurs in 5%-10% of AML. Its mutational landscape and prognostic significance are not well defined. A cohort of 156 trisomy AML patients was analysed, with reference to 615 cytogenetically normal (CN) AML patients. Trisomy AML showed distinct mutational landscape with more prevalent SMC1A, N/KRAS, ASXL1 and BCOR but fewer CEBPAbZIP and NPM1 mutations in patients ≤60, and fewer NPM1 mutations in those >60. NRAS mutations were associated with poor outcome in trisomy AML, whereas DNMT3A and FLT3-ITD mutations had neutral effect. Trisomy AML appeared biologically distinct from CN-AML.
Subject(s)
Leukemia, Myeloid, Acute , Nuclear Proteins , Humans , Nuclear Proteins/genetics , Nucleophosmin , Leukemia, Myeloid, Acute/genetics , Trisomy , Mutation , Karyotype , Prognosis , fms-Like Tyrosine Kinase 3/genetics
2.
Ann Hematol
; 100(5): 1337-1339, 2021 May.
Article
in English
| MEDLINE
| ID: mdl-33760949
Subject(s)
Clonal Evolution/physiology , Leukemia, Megakaryoblastic, Acute/genetics , Mediastinal Neoplasms/genetics , Neoplasms, Multiple Primary/genetics , Seminoma/genetics , Adult , Humans , Leukemia, Megakaryoblastic, Acute/diagnosis , Leukemia, Megakaryoblastic, Acute/therapy , Male , Mediastinal Neoplasms/diagnosis , Mediastinal Neoplasms/therapy , Mutation , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/therapy , PTEN Phosphohydrolase/genetics , Seminoma/diagnosis , Seminoma/therapy , Testicular Neoplasms/diagnosis , Testicular Neoplasms/genetics , Testicular Neoplasms/therapy , Tumor Suppressor Protein p53/genetics , Young Adult
3.
Ann Hematol
; 99(12): 2949-2952, 2020 Dec.
Article
in English
| MEDLINE
| ID: mdl-32514627
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Brentuximab Vedotin/administration & dosage , Epstein-Barr Virus Infections , Herpesvirus 4, Human/metabolism , Lenalidomide/administration & dosage , Lymphoma, T-Cell , Neoplasms, Second Primary , Positron Emission Tomography Computed Tomography , Aged , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Epstein-Barr Virus Infections/diagnostic imaging , Epstein-Barr Virus Infections/drug therapy , Epstein-Barr Virus Infections/etiology , Epstein-Barr Virus Infections/metabolism , Etoposide/administration & dosage , Humans , Lymphoma, T-Cell/diagnostic imaging , Lymphoma, T-Cell/drug therapy , Lymphoma, T-Cell/metabolism , Male , Neoplasms, Second Primary/diagnostic imaging , Neoplasms, Second Primary/drug therapy , Neoplasms, Second Primary/metabolism , Neoplasms, Second Primary/virology , Prednisolone/administration & dosage , Vincristine/administration & dosage
4.
Ann Hematol
; 94(7): 1245-6, 2015 Jul.
Article
in English
| MEDLINE
| ID: mdl-25828938
5.
Haematologica
; 100(7): e250-3, 2015 Jul.
Article
in English
| MEDLINE
| ID: mdl-25820334
Subject(s)
Antineoplastic Agents/therapeutic use , Azacitidine/therapeutic use , Leukemia, Myeloid, Acute/drug therapy , Niacinamide/analogs & derivatives , Phenylurea Compounds/therapeutic use , Protein Kinase Inhibitors/therapeutic use , fms-Like Tyrosine Kinase 3/antagonists & inhibitors , Animals , Apoptosis/drug effects , Cell Line, Tumor , Drug Administration Schedule , Drug Synergism , Gene Expression , Humans , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/mortality , Leukemia, Myeloid, Acute/pathology , Mice , Monocytes/drug effects , Monocytes/immunology , Monocytes/pathology , Mutation , Niacinamide/therapeutic use , Remission Induction , Sorafenib , Survival Analysis , Treatment Outcome , Xenograft Model Antitumor Assays , fms-Like Tyrosine Kinase 3/genetics , fms-Like Tyrosine Kinase 3/immunology
6.
Eur J Haematol
; 88(3): 275-6, 2012 Mar.
Article
in English
| MEDLINE
| ID: mdl-21848697
